CytomX Therapeutics, Inc.

Develops tumor-activated antibody therapeutics for more targeted, less toxic cancer treatments.

CTMX | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 151 OYSTER POINT BLVD., 94080 SOUTH SAN FRANCISCO
Website:: https://cytomx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing a novel class of investigational antibody therapeutics. The company's core technology is its proprietary Probody® platform, which is designed to create conditionally activated biologics. These therapeutics remain masked and inactive in healthy tissue but are activated specifically within the tumor microenvironment. This approach aims to enhance the therapeutic window, enabling more potent and targeted anti-cancer treatments with potentially reduced toxicity. CytomX is advancing a deep pipeline of Probody therapeutics, both independently and through strategic collaborations, to bring new treatment options to cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CytomX Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CytomX Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for CytomX Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Biosergen AB Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.	Sweden	BIOSGN
Bio Solution Co.,Ltd. Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.	South Korea	086820
Biosynex European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.	France	ALBIO
BIO-TECHNE Corp Develops reagents and instruments for life sciences research and clinical diagnostic markets.	United States of America	TECH
biote Corp. Trains practitioners in hormone optimization using bioidentical pellets and nutraceuticals.	United States of America	BTMD
Biotest AG Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.	Germany	BIO3
Biotika A.S. Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.	Slovakia	BSL
Bioton S.A. Develops and manufactures recombinant human insulin for global diabetes care solutions.	Poland	BIO
BIOVENTIX PLC Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.	United Kingdom	BVXP
Bioversys N Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.	Switzerland	BIOV